Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zai Lab Limited (NASDAQ: ZLAB).

Full DD Report for ZLAB

You must become a subscriber to view this report.


Recent News from (NASDAQ: ZLAB)

Week In Review: 2 China Biopharmas Raise $1.4 Billion In Hong Kong IPOs
Deals and Financings WuXi AppTec (SHA: 603259; HK: 2359) began trading on the Hong Kong Exchange following its $967 million IPO, finishing the first day of trading at the offer price. In May, the company completed a $354 million Shanghai IPO at a price that has now quadrupled after six month...
Source: SeekingAlpha
Date: December, 16 2018 09:56
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Deals and Financings BeiGene (BGNE) (HKEX:06160) of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks (ZYME) (see story ). BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispe...
Source: SeekingAlpha
Date: December, 02 2018 10:41
Zai Lab Limited Announces Presentations at November Conferences
SHANGHAI, China, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management team will be presenting at four upcoming events in November. Details of the presentations are as fol...
Source: GlobeNewswire
Date: November, 07 2018 07:30
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Deals and Financings Innovent Biologics has priced its Hong Kong IPO to raise $421 million, very close to the top of the expected range. The company set its offering price at HK$13.98, just below the top of the range. The successful IPO shows investors are still interested in young China bio...
Source: SeekingAlpha
Date: October, 28 2018 11:37
Zai Lab' ZEJULA for patients with relapsed ovarian cancer approved in Hong Kong
Zai Lab Limited ( ZLAB )  announces that its ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor is approved in Hong Kong for adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian cancer who are in a complete response or ...
Source: SeekingAlpha
Date: October, 22 2018 09:33
Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
ZEJULA is the first and only PARP inhibitor approved in Hong Kong for the maintenance treatment of platinum-sensitive relapsed ovarian cancer irrespective of BRCA mutation status Zai Lab expects to launch ZEJULA in Hong Kong in 4Q18 SHANGHAI, China, Oct. 22, 2018 (GLOBE NEWSWIRE) --...
Source: GlobeNewswire
Date: October, 22 2018 07:30
Cancer Research Highlight: Five Prime Moves To Prime Time With A New Phase 3 Trial Off The Ground
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. In the field of solid tumor on...
Source: SeekingAlpha
Date: October, 10 2018 08:00
Your Daily Pharma Scoop: Omeros Positive, Five Prime's Milestone
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other imp...
Source: SeekingAlpha
Date: October, 03 2018 13:29
Dosing underway in late-stage study of Five Prime's bemarituzumab in gastric cancer
Five Prime Therapeutics ( FPRX -1.2% ) and collaboration partner Zai Lab Limited ( ZLAB -0.8% ) announce that the first patient has been dosed in a Phase 3 clinical trial, FIGHT, evaluating bemarituzumab (FPA144) in patients with previously untreated advanced gastric cancer or gastroes...
Source: SeekingAlpha
Date: October, 01 2018 10:29
Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers
Phase 3 trial evaluating bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, and Zai Lab Limited (Nasdaq: ZLAB), a Shanghai-based ...
Source: Business Wire
Date: October, 01 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0818.2117.8118.3017.62505,849
2018-05-1721.1020.6121.1020.261251,850

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1434,19787,88638.9106Short
2018-12-1371,958152,83847.0812Short
2018-12-1211,09418,64659.4980Short
2018-12-116,12215,81138.7199Short
2018-12-103,92811,98032.7880Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZLAB.


About Zai Lab Limited (NASDAQ: ZLAB)

Logo for Zai Lab Limited (NASDAQ: ZLAB)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ZLAB)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: April, 30 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 25 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 05 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 26 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: ZLAB)

      Daily Technical Chart for (NASDAQ: ZLAB)


      Stay tuned for daily updates and more on (NASDAQ: ZLAB)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ZLAB)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZLAB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZLAB and does not buy, sell, or trade any shares of ZLAB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/